1 Followers
25 Following
chaitanyag11

chaitanyag11

Liver Fibrosis Treatment Market Study 2019: Impressively growing Opportunities

Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slowdowns further scarring of liver and results in improvement of condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolve of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.

Furthermore, research funding by various private research organizations to conduct research related to development of treatment for liver fibrosis and other fatty liver disease is expected to spur growth of liver fibrosis treatment market. For instance, in August 2018; professor from College of Science at Virginia Tech and Department of Pharmacology at the University of Virginia received US$ 400,000 grant from the Virginia Biosciences Health Research Corporation (VBHRC) with US$ 800,000 matching funds from Continuum Biosciences, Inc. This grant along with matching funds will help researchers to develop drugs to treat nonalcoholic steatohepatitis (NASH).

The global liver fibrosis treatment market size is expected to witness a CAGR of 10.8% over the forecast period (2018 – 2026) reaching a value of US$ 28.1 billion in 2026.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2320

Liver fibrosis results from various chronic injuries and it often progresses to liver cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Moreover, liver transplantation is only treatment available for advanced stage liver fibrosis. Therefore, new treatment strategies are currently in clinical development stages to treat the liver fibrosis. These treatment option include inhibition of hepatic injury, inhibition of activation of Hematopoietic Stem Cells (HSCs), and inhibition of proliferation of HSCs, inhibition of deposition of type I collagen and proliferation of HSCs. Treatment options for liver fibrosis are usually depends on the underlying cause of the fibrosis. A healthcare professional can treat the underlying liver fibrosis illness conditions, to reduce the effects of liver disease.

Furthermore, key players in the liver fibrosis treatment market are engaged in pre-clinical and clinical studies to develop novel treatment therapies in liver fibrosis regime. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for PTG-300: a subcutaneous injectable developed by Protagonist Therapeutics, Inc. The PTG-300 is currently in clinical development stage for the potential treatment of beta-thalassemia, and can also be used in the liver fibrosis treatment.

For instance, Gilead Sciences, Inc., in October 2017, released the Phase II result studies for Selonsertib: GS-0976 in Nonalcoholic Steatohepatitis (NASH) stage F3 liver fibrosis. These studies reported that, GS-0976 led to significant reductions in concentration of liver fat and fibrosis. Moreover, Gilead Sciences also contain 18 other pipeline molecules in the liver fibrosis treatment, which is further expected to boost company’s revenue in near future.In April 2017, Tobira Therapeutics, Inc. initiated the clinical study to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult patients with NASH. The study is expected to complete in July 2019.

In April 2017, Bristol-Myers Squibb Company presented the Phase II clinical trial study of BMS-986036: a human fibroblast growth factor. The study results reported that BMS-986036 shows consistent improvement in liver fat, liver injury, and liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH). Increasing number of clinical trials are currently in process for the treatment of liver fibrosis, which are expected to augment the market growth over the forecast period.

Click To Reading More On Liver Fibrosis Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Liver Fibrosis Treatment Market Study 2019: Impressively growing Opportunities

Furthermore, research funding by various private research organizations to conduct research related to development of treatment for liver fibrosis and other fatty liver disease is expected to spur growth of liver fibrosis treatment market. For instance, in August 2018; professor from College of Science at Virginia Tech and Department of Pharmacology at the University of Virginia received US$ 400,000 grant from the Virginia Biosciences Health Research Corporation (VBHRC) with US$ 800,000 matching funds from Continuum Biosciences, Inc. This grant along with matching funds will help researchers to develop drugs to treat nonalcoholic steatohepatitis (NASH).

The global liver fibrosis treatment market size is expected to witness a CAGR of 10.8% over the forecast period (2018 – 2026) reaching a value of US$ 28.1 billion in 2026.

Diathermy Equipment Market Opportunities in Upcoming years 2019

Diathermy is a controlled production of ‘deep heating’ beneath the skin in the subcutaneous tissues, deep muscles, and joints for therapeutic purposes. Using high-frequency short wave electric currents, the heat is generated in the diathermy equipment. The heat can reach areas as deep as two inches beneath the skin’s surface. Diathermy equipment does not apply heat directly to the body. Instead, the waves generated by the machine allow the body to generate heat from within the targeted tissue. Diathermy equipment is used to treat several conditions such as chronic arthritis, fibromyalgia, tendonitis, bursitis, muscle spasms, and increasing blood flow. Diathermy is widely used in surgical procedures to reduce muscle pain and to speed up recovery.

Global Diathermy Equipment Market: Drivers

The diathermy equipment market size is expected to witness significant growth, owing to increasing prevalence of arthritis and other muscle related disorders and high demand for diathermy treatment. Diathermy treatment for arthritis is very effective and efficient. According to National Health Interview Survey (NHIS) from 2013 to 2015, around 54.4 million U.S. adults (22.7%) were diagnosed with arthritis, rheumatoid arthritis, gout, or fibromyalgia.

Diathermy is an integral part of several modern surgical procedures, which directly contribute to diathermy equipment market revenue. Diathermy equipment are widely used in surgeries for electrosurgical cutting, coagulation, fulguration, and desiccation. According to National Center for Biotechnology Information (NCBI), around 80% of surgical procedures involve the use of diathermy equipment to apply energy to tissues.

Request A Sample Copy Of This Report:

https://www.coherentmarketinsights.com/insight/request-sample/2519

Global Diathermy Equipment Market: Restraints

Lack of adequate knowledge and training about diathermy equipment is one of the major restraining factors for diathermy equipment market growth. According to NCBI 2016 report, in Ireland, 57% of surgeons lack adequate knowledge and awareness in managing diathermy equipment.

Diathermy equipment generate heat with the help of high-frequency short wave electric currents using electrodes. Several cases of surgical burns and fire were reported while using these equipment leading to burns and certain injuries when the heat limit is exceeded. According to U.S. Food and drug Administration (FDA), the heat produced by diathermy equipment in tissue should be a minimum of 104 degree F to a maximum of 114 degree F at a depth of two inches in not more than 20 minutes. According to NCBI, as reported in 2017, around 500 to 600 surgical fires occur annually in the U.S., owing to lack of proper training in equipment handling.

Global Diathermy Equipment Market: Regional Analysis

North America is expected to hold dominant position in the global diathermy equipment market over the forecast period due to increasing incidences of musculoskeletal disorders such as arthritis, fibromyalgia, tenosynovitis, and tendonitis. According to American Academy of Orthopedic Surgeons’ (AAOS) March 2016 estimates, around 126.6 million people in the U.S. are suffering from musculoskeletal disorders.

Asia Pacific is expected to witness significant growth in the market, owing to presence of key manufacturers and vendors of diathermy equipment in the region. Majority of market players in the diathermy equipment market such as Zhejiang Jinhua Huatong Medical Appliance Co., Beijing Greenland Science & Technology Developments, Physio International, Medcorpindia, and Micro Electronics Medicines belong to Japan, India, South Korea, and Singapore.

Key players operating in the global diathermy equipment market include, Physio International, Zhejiang Jinhua Huatong Medical Appliance Co., Pioneer Health Care, Schiller Healthcare India, Medcorpindia, Tri Tech, Micro Electronics Medicines,United Medical Appliances, Nanjing Fuzhong Medical High-Tech. Co., Beijing Greenland Science & Technology Developments, Life Care Systems, Sunshine Medical Equipment, Sometech Inc., and Spark Meditech.

Click To Reading More On Diathermy Equipment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Diathermy Equipment Market Opportunities in Upcoming years 2019

Diathermy is a controlled production of ‘deep heating’ beneath the skin in the subcutaneous tissues, deep muscles, and joints for therapeutic purposes. Using high-frequency short wave electric currents, the heat is generated in the diathermy equipment.

Nerve Repair and Regeneration Market Growth Analysis, Competitor Landscape, Opportunity

The delicate and complex structures that make up the nervous system consists of spinal cord, brain and peripheral nerves. They are prone to various types of disorders such Alzheimer’s disease, Amyotrophic lateral sclerosis, Parkinson’s disease, multiple system atrophy, and multiple sclerosis. Nerve repair and regeneration refers to repair and regrowth of nervous cells or tissues. It usually includes various mechanisms like generation of new glia, neurons, axons, myelin and synapses. Nerve Regeneration is segmented between the Peripheral Nervous System (PNS) and Central nervous system (CNS). CNS consists of the brain and spinal cord and PNS consists of spinal and cranial nerves along with their associated ganglia. PNS has an intrinsic ability of regeneration whereas CNS is not capable of repair and regeneration. Clinical treatments of nerve repair and generation include surgery, nerve grafting, allografts, and xenografts. Surgery includes of different types such as stem cell therapy, nerve grafting, and direct neuropathy. Stem cell therapy uses stem cells to treat disorders such as neuromuscular and degenerative disorders. Nerve grafting is a surgical technique, which includes repairing injured portion of the nerve by using a segment of unrelated nerve as a bridge to join the injured nerve.

Nerve Repair and Regeneration Market Dynamics:-

Major growth factor for nerve repair and regeneration market is the growing prevalence of neurological disorders. According to a survey conducted by National Health Interview survey (NHIS) in 2014, and estimated 1.4 million people suffer from nerve injuries and around 900,000 people undergo surgeries for neurological disorders. Moreover, new drugs for nerve repair and regeneration in the pipeline are expected to boost growth of the nerve repair and regeneration market over the forecast period. For instance, Axogen Inc. a U.S.-based company received an approval from Food and Drug Administration (FDA) in 2015 to proceed with RECON STUDY to support an investigational new drug application. RECON study is a prospective, multicenter, randomized study to evaluate surgical repairs outputs of peripheral nerve disorders. It is currently in phase 3 clinical trial. Furthermore, mergers and acquisitions by key market players are expected to fuel growth of the market. For instance, AxoGen a U.S.-based company, which is a leading company in nerve regeneration partnered with LifeNet Health, a leading allograft bio-implant company for the processing of advanced nerve grafts. This partnership is expected to improve the access for treatment of patients suffering from peripheral nerve disorder, which in turn is expected to fuel growth in global nerve repair and regeneration market.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1762

However, stringent rules and regulation for approval of new drugs and high cost of nerve repair and regeneration devices and surgeries are key factors restraining growth of the nerve repair and regeneration market size.

Nerve Repair and Regeneration Market Regional Analysis:-

North America nerve repair and regeneration market is expected to hold dominant position and is expected to witness significant growth over the forecast period, owing to adoption of inorganic growth model by key players for geographic expansion. For instance, in January 2018, NeuroMetrix and GlaxoSmithKline Plc. (GSK) consumer health care merged to increase and develop new Quell Wearable pain release technology, this is a non-invasive device used to treat and manage chronic pain associated by nerve repair surgeries. GSK Consumer healthcare acquired ownership of Quell Technology for markets outside U.S. In 2018 Collagen Matrix a U.S. based company launched OssiMend Spine and Dura Matrix Dural Repair products, OssiMend is a bone graft matrix which is used to provide scaffold to a patient to help them grow a new bone. Dura Matrix provides scaffold to brain and spinal cord. Europe nerve repair and regeneration market is expected to grow at significant rate, owing to increasing prevalence of neurological disorders. According to a study conducted by National Institute of health (NIH), in 2017, Alzheimer’s disease is reported to be the most common type of dementia. Increasing number of geriatric population is in turn increasing number of patients suffering from Alzheimer disorder, around 16.51 million people are diagnosed with Alzheimer in Europe between 2014 and 2016.

Nerve Repair and Regeneration Market Key Players:-

Key players operating in nerve repair and regeneration market include AxoGen, Boston Scientific, Liva Nova, Integra Life Sciences, Medtronic, Abbott Laboratories, Stryker, Nevro, Polyganics, Neuvectra, OrthoMed S.A.S, St. Jude Medical, Cyberonics Inc., and others.

Click To Reading More On Nerve Repair and Regeneration Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Nerve Repair and Regeneration Market Growth Analysis

The delicate and complex structures that make up the nervous system consists of spinal cord, brain and peripheral nerves. They are prone to various types of disorders such Alzheimer’s disease, Amyotrophic lateral sclerosis, Parkinson’s disease, multiple system atrophy, and multiple sclerosis.

Insomnia therapeutics Market Key Findings with Worldwide Top Companies

Insomnia is a common type of sleep disorder and frequently co-morbid with mental or psychiatric illness. Consistent risk factors for insomnia are age, and stress associated with job, family, financial, and medical conditions.

Insomnia therapeutics Market Key Findings with Worldwide Top Companies

Insomnia is a common type of sleep disorder and frequently co-morbid with mental or psychiatric illness. Consistent risk factors for insomnia are age, and stress associated with job, family, financial, and medical conditions. Increase in consumption of alcohol, caffeine, nicotine could also lead to insomnia. Depending on the duration, insomnia is categorized into transient and chronic insomnia. Transient insomnia last for a single night to few weeks or months and is an adaptive response to the above mentioned challenges. Chronic insomnia is more complex resulting from combination of factors mentioned above and lasts for longer period of time. Insomnia is normally treated with prescription medication or over the counter sleep aid such as natrol melatonin and unisom sleep gel help people to fall asleep with minimum side effects. According to a study by University of Laval, 2011, about 40 % of the adult Canadian are experiencing one or more symptoms of insomnia. Further, a latest research reported in Nature, 2017, stated that insomnia increases the risk in women to deliver premature babies by 30%. Increase in incidence of insomnia across the globe will propel the insomnia therapeutics market.

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/958

New improved medication with lesser side effects will drive the insomnia therapeutics market growth globally

Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period.

Intermezzo (2014), are used in small doses and administered under the tongue for faster absorption. Tesimelton approved by FDA in 2014 is the only drug approved by FDA for Non-24-Hour Sleep-Wake Rhythm Disorder and it lacks abuse potential. These products are expected to drive the insomnia therapeutics market over the forecast period.

Increasing awareness and treatment seeking rates for insomnia are expected to further contribute to the growth of the market. However, the loss of exclusivity of the drugs led the market more genericized, creating a competitive environment for new entrants. For instance, non-benzodiazepines and low dose sedating anti-depressants, still considered as a first line of medication for the insomnia, are facing stiff competition from the generics.

According to a report by Sleep Research Society, 2012, 20% of the general adult population in Canada and U.S is suffering from insomnia and this number is expected to increase in the near future. Problems like daytime sleepiness, and fatigue is affecting larger number of population and imposing a considerable burden on these regions. These factors all together will trigger the total insomnia therapeutics market demand in the future period.

Devices would have a negative impact on the global insomnia therapeutics market

Rapid entry of new players and new devices for insomnia will boost the market over the forecast period. FDA approved new device Cerêve Sleep System for insomnia in 2016 this device is used to reduce latency to stage 1 and stage 2 sleep by keeping the forehead cool. Major players in insomnia therapeutics market are GlaxoSmithKline plc, UCB Group, Otsuka Holdings Co., Ligand Pharmaceuticals Incorporated, Axxonis Pharma AG, Kyowa Hakko Kirin Co. Ltd., National Institute of Neurological Disorders and Stroke, Jazz Pharmaceuticals, Inc. Ltd., Omeros Corporation and Manhattan Pharmaceuticals, Inc.

Click To Reading More On Insomnia therapeutics Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Latex Medical Disposables Market 2019: Industry Landscape

Latex medical disposables are used as primary wearables for safety and precaution while performing medical procedures such as surgeries, check-ups, and diagnostic tests in the hospitals, clinics, and laboratory centers.

Latex Medical Disposables Market 2019: Industry Landscape And Acknowledgement

Latex medical disposables are used as primary wearables for safety and precaution while performing medical procedures such as surgeries, check-ups, and diagnostic tests in the hospitals, clinics, and laboratory centers. The most widely used latex medical disposables are latex gloves, which are being used in massive quantities among the doctors, surgeons, dentists, and several other medical professionals across the world. The medical disposables are generally used to avoid contamination between the examiner and the patient. These disposables prevent transfer of infectious reagents from the healthcare personnel to the patient. Powdered latex gloves and powder-free latex gloves are two types of latex gloves. The powder-free latex gloves are high in demand due to its hassle-free properties and increased safety levels. The latex medical disposables also consists of various other products, which includes latex urine bags, catheters, and probes.

Market Dynamics

The annual rise in the number of surgeries performed globally increases the demand for latex nitrile disposable gloves, thereby driving growth of the global latex medical disposables market. According to the World Health Organization (WHO), over 232 million surgeries were performed across the world in 2013. All the simple as well as critical surgical procedures demands the use of safety gloves as a pre-requisite. Other factors driving growth of the global latex medical disposables market include rising prevalence of chronic kidney diseases that requires dialysis treatment as well as surgeries that make use of Foley catheters. According to a survey by the Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco in 2013, over 650,000 patients in the U.S. were affected by end-stage renal disease (ESRD) that demand dialysis. Moreover, according to the National Kidney Foundation, over 2 million people across the globe are currently receiving treatments for kidney diseases in the form of dialysis or transplant. The increasing use of disposable latex urine bags by patients vulnerable to dialysis further boost growth of the global latex medical disposables market. However, sensitivity and allergy towards latex is the only factor that might hamper growth of the global latex medical disposables market. According to the American Latex Allergy Association, around 8%-17% of the health care professionals are allergic to latex.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1730

Regional Insights:

On the basis of region, the global latex medical disposables market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global market, followed by Europe, owing to the increasing concern towards safety while performing medical procedures, as well as increasing measures to prevent contagious diseases. According to a fact sheet by the National Kidney Foundation in 2017, around 6.7% of the total Medicare budget is contributed towards the treatment of chronic kidney diseases. This suggests high demands for latex urine dialysis bags, as dialysis serves as a promising treatment for patients suffering from stage 2 and end stage kidney disease. Asia Pacific is expected to generate high revenue over the forecast period, owing to rapid developments in healthcare infrastructure and increasing number of surgeries in economies of this region such as China, India, Japan, Malaysia, and Singapore. According to the statistics by Lancet Commission of Global Surgery in 2016, with 14,833 surgical procedures per 100,000 people, highest rates of surgeries are performed in Japan. Several other factors responsible for market growth in these economies include rise in per capita income and flourishing healthcare, medical, and pharmaceutical sectors within these economies.

Competitive Landscape:

The key players operating in the global latex medical disposables market include Supermax Corporation Berhad, Hartalega Holdings Bhd, C.R. Bard, B. Braun Melsungen, Dynarex Corporation, Top Glove Corporation, and Medtronic Plc. The market players are focused towards providing innovative products that are infection free to increase their customer base. For instance, in May 2018, Symphony Environmental Technologies Plc introduced the first disposable antimicrobial latex examination gloves made with d2p technology for complete hygiene and elimination of risks of antimicrobial infection from latex.

Click To Reading More On Latex Medical Disposables Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Home Medical Equipment Market Detailed Study Of Business Growth,Development Factors

Home medical equipment refers to cost-effective medical devices that help provide safe and effective treatment to patients in the comfort of their home. This significantly reduces stress related to treatment and helps in speedy recovery of patients and improves their quality of life. Home healthcare equipment is also called durable medical equipment (DME), as it is projected to tolerate repeated use by non-professionals or the patient, and is appropriate for use in home settings. It typically includes medical electric equipment such as digital blood pressure monitors, blood glucose meters, pulse oximeters, and peak flow meters.

Home Medical Equipment Market Detailed Study Of Business Growth,Development Factors

Home medical equipment refers to cost-effective medical devices that help provide safe and effective treatment to patients in the comfort of their home. This significantly reduces stress related to treatment and helps in speedy recovery of patients and improves their quality of life. Home healthcare equipment is also called durable medical equipment (DME), as it is projected to tolerate repeated use by non-professionals or the patient, and is appropriate for use in home settings. It typically includes medical electric equipment such as digital blood pressure monitors, blood glucose meters, pulse oximeters, and peak flow meters. These devices are available in both hospital and home-use models, with changing features and capabilities differentiating the models. The term home healthcare equipment is also applied to products such as breast pumps, nebulizers, and artificial limbs and other prosthetic devices. Personal hygiene products, electric toothbrushes, and denture cleaners may also be covered under this broad segment. Even mechanical assist devices, such as wheelchairs, seat lifts, and walkers can be part of home healthcare equipment. It helps in reducing duration of patients’ stay in hospitals, nursing homes, or clinics.

Growing geriatric population, rising incidence of chronic diseases, and growing healthcare expenditure are some of the key factors driving growth of the global home medical equipment market. Increasing consumer awareness about the convenience and cost effectiveness of deploying such products, increase in the patient preference for home-based care, rising insured population as a result of the Affordable Care Act, technological advancements such as wearable devices, tele health, mobile health applications, etc. further spur growth of the market.

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/233

Home Medical Equipment Market

On the basis of product type, the global market is segmented into:

Home Tests and Patient Monitoring Equipment

Home Therapeutic Equipment

Patient Support Equipment

In home medical equipment market, North America is the largest geographic region, followed by Europe. This is mainly attributed to robust healthcare infrastructure, technological advancement, high disposable income, and good reimbursement policies in the region. In the U.S., provisions of the Obamacare Act that provides health insurance to 30 million uninsured people in the country creates a highly conducive environment for growth of the home medical equipment market. Increasing demographics and rising healthcare spending in emerging economies such as India and China are further expected to favor growth of the market in home medical equipment. The market in the Asia Pacific region is expected to experience high growth rate in the near future due to increasing awareness and shortage of professional medical services providers in the region. Furthermore, technological innovation have led to development of advancement products which would augment growth of the market. In the global home medical equipment industry, an increasing number of mergers and acquisitions and new product launches are the latest trends that have been observed in the recent past.

Changing reimbursement policies, risk to safety, limited insurance coverage, and health of home healthcare worker, and growing patient safety concerns such as home healthcare worker have less control over their work environment that may contain a number of safety and health hazards. These hazards which may include ergonomic hazards, bloodborne pathogens and biological hazards, latex sensitivity, from patient lifting, hostile animals violence, and unhygienic and dangerous conditions. Additionally, if their daily work duties requires them to provide care for multiple patients, they may face hazards on the road as they drive from home to home, these  are some of the main factors projected to inhibit growth of this market during the forecast period. The U.S. FDA has regulated medical devices used by consumers at home in the same way it regulates all other medical devices. However, in recognition of the growing number of potential safety issue regarding the use of home healthcare equipment, the FDA announced plans to provide closer oversight of home healthcare equipment in the United States in April 2010.

Key players operating in the global home medical equipment market are AstraZeneca, B. Braun Melsungen AG, Baxter, GE Healthcare, F. Hoffmann-La Roche Ltd, Stryker, Sunrise Medical LLC, ResMed, Philips Healthcare., Medline Industry, CareFusion Corporation, and Abbott Laboratories.

Click To Reading More On Home Medical Equipment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Transthyretin Amyloidosis Treatment Market Advanced Business Strategies

Hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis are two main types of transthyretin amyloidosis. hATTR is further classified into Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC). Wild type variant (ATTRwt) predominantly affects the heart.

Transthyretin Amyloidosis Treatment Market Advanced Business Strategies & Competitive Dynamics

Hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis are two main types of transthyretin amyloidosis. hATTR is further classified into Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC). Wild type variant (ATTRwt) predominantly affects the heart.

Transthyretin amyloidosis is a result of transthyretin produced by the liver and forms dimers, followed by monomers. Monomers aggregate to form amyloid fibrils, which are deposited in organs such as heart, nervous system, gastrointestinal tract, and kidneys. FAP is a subtype of hereditary transthyretin amyloidosis and the most common type of FAP is caused by the Val30Met variant of Transthyretin (TTR). In familial amyloid polyneuropathy, the symptoms are first detected after the patient crosses 30 years of age, however, it can also be detected as early as 20 years or as late as 80 years of age. Symptoms are divided depending on the location such as peripheral neuropathy and autonomic neuropathy. Symptoms may worsen in case excess amyloid protein starts to collect in the nerves.

Introduction of novel therapy for the treatment of transthyretin amyloidosis is expected to significantly drive the market growth

Key players in the market are focused on approval and launch of novel therapies for treatment of transthyretin amyloidosis. This in turn is expected to propel growth of the global transthyretin amyloidosis treatment market over the forecast period. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

In July 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received marketing authorization approval for its drug TEGSEDI (inotersen) from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

The global transthyretin amyloidosis treatment market size is expected to be valued at US$ 35.8 million in 2018 and is expected to witness a robust CAGR of 55.4% over the forecast period (2018–2026).

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/687

Major players in the market have novel drugs in the pipeline, which are in late-stage clinical trials and are expected to receive approval in the near future. For instance, Eidos Therapeutics, Inc. is developing AG10— an orally-administered, small molecule designed to potently and selectively stabilize tetrameric TTR, thereby interfering with events that give rise to ATTR. The drug is currently in Phase 2 clinical trial.

Akcea Therapeutics Inc. is co-developing AKCEA-TTR- LRx with Ionis Pharmaceuticals to inhibit the production of transthyretin. Akcea Therapeutics Inc. is focused on developing AKCEA-TTR-LRx for patients with both hereditary and wild type form of the disease. AKCEA-TTR-LRx is planning to enter clinical development in 2018. Key players in the market are focused on strategic partnerships in order to enhance their market share. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. partnered with Orsini Healthcare, a specialty pharmacy as distributor of ONPATTRO (patisiran) lipid complex injection.

However, high costs of recently launched drugs is expected to hinder growth of the market. For instance, according to Alnylam Pharmaceutical, Inc., the cost of Patisiran is around US$ 450,000, annually before insurance. Another drug, Inotersen manufactured by Ionis Pharmaceuticals in partnership with Akcea Therapeutics, received approval for hereditary Transthyretin Amyloidosis Polyneuropathy indication and the drug costs US$ 450,000, annually. High cost of drugs may result in lower adoption even in developed economies such as the U.S., thereby restraining growth of the market.

Key players operating in the global transthyretin amyloidosis treatment market include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR. In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.

Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type. Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.

Click To Reading More On Transthyretin Amyloidosis Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Electroencephalography Market Insight By Advanced Business Strategies & Competitive Dynamics

Electroencephalography, commonly termed as EEG, refers to a physiological method of choice that facilitates recording of electrical activity generated by the brain from electrodes placed on the surface of the scalp.

Electroencephalography Market Insight By Advanced Business Strategies & Competitive Dynamics

Electroencephalography, commonly termed as EEG, refers to a physiological method of choice that facilitates recording of electrical activity generated by the brain from electrodes placed on the surface of the scalp. The EEG measures electrical activity generated by the synchronized activity of thousands of neurons that helps to analyze the activated areas of brain at a particular instance. The EEG also acts as a helpful measure to diagnose various neurological disorders such as Alzheimer’s disease, dementia, epilepsy, autism by determining the malfunction produced in the normal electrical signal pattern. The neurons in the brain generate electrical impulses that fluctuate in a rhythmic and distinct pattern. The accuracy and price differences in the electroencephalography devices available in the market depends on the number of electrodes that are present in the crown of the EEG system. Systems with high number of electrodes provides high quality digitalization, better quality amplification, and higher number of snapshots taken by device per second as compared to systems with few electrodes. Electroencephalography can also be used as an important tool in assessment of patients suspected with brain death. EEG waveforms report immediate signals to remove the brain in case of transplantation and storage of the dead brain.

The global electroencephalography devices market was valued at US$ 704.4 million in 2016 and is expected to witness a robust CAGR of 7.0% over the forecast period (2017–2025).

Among region, North America holds the dominant position in the global electroencephalography devices market. This is attributed to rapid development and launch of novel EEG devices and systems by key players in the market. For instance, in October 2015, Brain Products GmbH, a U.S.-based company introduced LiveAmp, an ultra-lightweight wearable amplifier that allows the users to store data internally without any mobility limitations. U.S.-based manufacturers are also incorporating Artificial Intelligence (AI) technology in their devices so as to make the systems smarter and reduce expertise requirement for their operation. For instance, in March 2017, EEG Enterprises introduced Lexi, a new cloud hosted service that connects the company’s existing EEG workflows with speech recognition technology.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1665

Asia Pacific is expected to exhibit highest growth over the forecast period, owing to the increasing number of Asia-based companies entering into the international markets is expected to enhance the regional growth. For instance, in November 2017, Nihon Kohden Corporation, Japan-based medical device company, started a new sales branch in Kenya with an aim to expand its sales in the East Africa, as a part of its strategic business expansion. Moreover, the authorities in countries are easing regulations and guidelines of medical devices to increase the export of devices from the region, is in turn, boosting market growth. For instance, in January 2013, Japanese government officially declared easing of regulations and manufacturing guidelines for medical equipment to leverage the medical companies for increasing their production scales and invent revolutionary medical devices that can be valued significantly in the international markets.

Market players are engaged in innovative product launches to sustain their position in the global electroencephalography devices market

Key players in the market are focused on expansion of their presence through launch of new product lines in emerging economies. For instance, in September 2016, BrainScope Company, Inc. received FDA clearance for the first handheld medical device for the assessment of full spectrum of traumatic brain injury. This device was developed in partnership with the U.S. department of defense, to offer a comprehensive panel of data to clinicians that would assist in the diagnosis of the full spectrum of TBI. Moreover, in October 2015, Brain Products GmbH conducted official market launch of LiveAmp, an ultra-lightweight, wireless wearable amplifier that allows internal data storage without any mobility limitations. The system serves to be an ideal brain activity analyzer for applications in sports injuries, sleep state monitoring, and cognitive research.

Key players operating the global electroencephalography devices market include Natus Medical, Inc., BrainScope Company, Inc., Medtronic Plc, NeuroWave Systems, Inc., Compumedics Limited, Electrical Geodesics, Inc., Cadwell Industries, Inc., Jorden Neuroscience, Inc., and others.

Click To Reading More On Electroencephalography Devices Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com